Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Q4 2021 vs. Q3 2021
How the institutions holding Trevi Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 18 | 1 | 17 | 0 |
| Shares | 12.4M | 4.82M | 13.2M | +5.55M (+72.8%) |
| Value | $17.4M | $6.75M | $10.3M | −$381.0K (−3.6%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Trevi Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| TPG GP A, LLC | 4,824,883 | $3.77M | 0.04% |
| Armistice Capital, LLC | 1,512,344 | $1.18M | 0.03% |
| Millennium Management LLC | 121,492 | $95.0K | 0.00% |
| Ground Swell Capital, LLC | 10,461 | $8.00K | 0.05% |
Sold out (4)
Institutions that held Trevi Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Omega Fund Management, LLC | 1,263,408 | $1.77M |
| UBS Group AG | 5,173 | $7.00K |
| Barclays PLC | 100 | $0 |
| Harbour Investments, Inc. | 250 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Trevi Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| TPG Group Holdings (SBS) Advisors, Inc. | 4,824,883 | $6.75M |